New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:58 EDTVRX, AGNAllergan has many other strategic options, says BMO Capital
After meeting with Allergan's (AGN) management, BMO Capital says that the company has many strategic options other than the takeover bid from Valeant (VRX). The firm thinks that Allergan's outlook as a standalone company is strong, and it believes there is less than a 50% chance that Valeant will acquire Allergan. The firm keeps an Outperform rating on Allergan.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use